Editas Medicine, Inc. (EDIT) Financial Analysis & Valuation | Quarter Chart
Editas Medicine, Inc. (EDIT)
EDITPrice: $2.32
Fair Value: 🔒
🔒score
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial... more
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative... more
Description
Shares
| Market Cap | $227.06M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Gilmore O'Neill |
| IPO Date | 2016-02-03 | CAGR | — |
| Employees | 246 | Website | www.editasmedicine.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.16% | Total Yield | -0.16% |
EDIT chart loading...
Fundamentals
Technicals
| Enterprise Value | $32.50M | P/E Ratio | -1.29 |
| Forward P/E | -3.41 | PEG Ratio | — |
| P/S Ratio | 3.43 | P/B Ratio | 4.64 |
| P/CF Ratio | -0.76 | P/FCF Ratio | -0.84 |
| EPS | $-1.8 | EPS Growth 1Y | -34.45% |
| EPS Growth 3Y | -38.71% | EPS Growth 5Y | -5.61% |
| Revenue Growth 1Y | 25.4% | Gross Margin | 0.98% |
| Operating Margin | -2.45% | Profit Margin | -3.95% |
| ROE | -5.23% | ROA | -0.86% |
| ROCE | -0.71% | Current Ratio | 3.54 |
| Quick Ratio | 3.54 | Cash Ratio | 3.17 |
| Debt/Equity | 0.66 | Interest Coverage | — |
| Altman Z Score | -10.35 | Piotroski Score | 1 |